FDA Reviews Possible Mirapex Heart Risk – MedPage Today

by admin on September 19, 2012

FDA Reviews Possible Mirapex Heart Risk
MedPage Today
Epidemiological data suggest that pramipexole (Mirapex), used to treat Parkinson's disease and restless legs syndrome, is associated with an increased risk of heart failure, the FDA said. Pooled data from randomized trials with the dopamine agonist, as
FDA warns of potential heart failure risk with pramipexoleTheHeart.Org
Mirapex May Increase Heart Failure Risk, FDA SaysLaw360 (subscription)
Mirapex (pramipexole): Drug Safety Communication – Ongoing Safety Review Bioscience Technology

all 4 news articles »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: